The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial
Open accessAbstract
OBJECTIVE: To determine whether ciclosporin is superior to prednisolone for the treatment of pyoderma gangrenosum, a painful, ulcerating skin disease with a poor evidence base for management. DESIGN: Multicentre, parallel group, observer blind, randomised controlled trial. SETTING: 39 UK hospitals, recruiting from June 2009 to November 2012. PARTICIPANTS: 121 patients (73 women, mean age 54 years) with clinician diagnosed pyoderma gangrenosum. Clinical diagnosis was revised in nine participants after randomisation, leaving 112 participants in the analysis set (59 ciclosporin; 53 prednisolone). INTERVENTION: Oral prednisolone 0.75 mg/kg/day compared with ciclosporin 4 mg/kg/day, to a maximum dose of 75 and 400 mg/day, respectively. MAIN OUTCOME MEASURES: The primary outcome was speed of healing over six weeks, captured using digital images and assessed by blinded investigators. Secondary outcomes were time to healing, global treatment response, resolution of inflammation, self reported pain, quality of life, number of treatment failures, adverse reactions, and time to recurrence. Outcomes were assessed at baseline and six weeks and when the ulcer had healed (to a maximum of six months). RESULTS: Of the 112 participants, 108 had complete primary outcome data at baseline and six weeks (57 ciclosporin; 51 prednisolone). Groups were balanced at baseline. The mean (SD) speed of healing at six weeks was -0.21 (1.00) cm(2)/day in the ciclosporin group compared with -0.14 (0.42) cm(2)/day in the prednisolone group. The adjusted mean difference showed no between group difference (0.003 cm(2)/day, 95% confidence interval -0.20 to 0.21; P=0.97). By six months, ulcers had healed in 28/59 (47%) participants in the ciclosporin group compared with 25/53 (47%) in the prednisolone group. In those with healed ulcers, eight (30%) receiving ciclosporin and seven (28%) receiving prednisolone had a recurrence. Adverse reactions were similar for the two groups (68% ciclosporin and 66% prednisolone), but serious adverse reactions, especially infections, were more common in the prednisolone group. CONCLUSION: Prednisolone and ciclosporin did not differ across a range of objective and patient reported outcomes. Treatment decisions for individual patients may be guided by the different side effect profiles of the two drugs and patient preference. Trial registration Current Controlled Trials ISRCTN35898459.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Variations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059
Brooklyn, T. N., Dunnill, M. G. S., Shetty, A., Bowden, J. J., Williams, J. D. L., Griffiths, C. E. M., Forbes, A., Greenwood, R., & Probert, C. S. (2006) · Gut · doi:10.1136/gut.2005.074815 · Cited by 646
Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria
Su, W. P. D., Davis, M. D. P., Weenig, R. H., Powell, F. C., & Perry, H. O. (2004) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2004.02128.x · Cited by 580
Reichrath, J., Bens, G., Bonowitz, A., & Tilgen, W. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.10.006 · Cited by 407
Binus, A. M., Qureshi, A. A., Li, V. W., & Winterfield, L. S. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10565.x · Cited by 404
British Association of Dermatologists
Dobson, R. L. (1979) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(79)80076-6 · Cited by 285
Diagnosis and treatment of pyoderma gangrenosum
Brooklyn, T., Dunnill, G., & Probert, C. (2006) · BMJ · doi:10.1136/bmj.333.7560.181 · Cited by 275
Langan, S. M., Groves, R. W., Card, T. R., & Gulliford, M. C. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.130 · Cited by 257
Cited by
Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts
Maverakis, E., Ma, C., Shinkai, K., Fiorentino, D., Callen, J. P., Wollina, U., Marzano, A. V., Wallach, D., Kim, K., Schadt, C., et al. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.5980 · Cited by 452
Self-citationPyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment
Alavi, A., French, L. E., Davis, M. D., Brassard, A., & Kirsner, R. S. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0251-7 · Cited by 321
ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
Gordon, H., Burisch, J., Ellul, P., Karmiris, K., Katsanos, K., Allocca, M., Bamias, G., Barreiro-de Acosta, M., Braithwaite, T., Greuter, T., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjad108 · Cited by 318
Maverakis, E., Marzano, A. V., Le, S. T., Callen, J. P., Brüggen, M.-C., Guenova, E., Dissemond, J., Shinkai, K., & Langan, S. M. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0213-x · Cited by 285
Naudet, F., Sakarovitch, C., Janiaud, P., Cristea, I., Fanelli, D., Moher, D., & Ioannidis, J. P. A. (2018) · BMJ · doi:10.1136/bmj.k400 · Cited by 227
Metadata
- Authors
- Ormerod, A. D., Thomas, K. S., Craig, F. E., Mitchell, E., Greenlaw, N., Norrie, J., Mason, J. M., Walton, S., Johnston, G. A., Williams, H. C., & on behalf of the UK Dermatology Clinical Trials Network's STOP GAP team
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2015-06-12
- Volume
- 350
- Issue
- jun12 3
- Pages
- h2958-h2958
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2270887188
- Cited by
- 273
- References
- 16
- FWCI
- 18.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. https://app.cochat.ai/papers/10.1136/bmj.h2958
- The paper
- Ormerod, A. D., Thomas, K. S., Craig, F. E., Mitchell, E., Greenlaw, N., Norrie, J., Mason, J. M., Walton, S., Johnston, G. A., Williams, H. C., & on behalf of the UK Dermatology Clinical Trials Network's STOP GAP team. (2015). Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. https://doi.org/10.1136/bmj.h2958
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.